FDA Warns Novo Nordisk on Unreported Deaths CEO & Founder at LlamaLab FDA Cites 'Systemic Failures' in Novo Nordisk's Reporting of Ozempic Deaths The FDA issued a warning letter to Novo Nordisk on March 5, 2026, citing "systemic failures" in the company's adverse event reporting for its semaglutide and liraglutide drugs including at least two unreported patient deaths and a suicide case that had still not been submitted to the FDA as of the letter's date
1 This expansion is driven by more than just obesity
however, their administration is frequently accompanied by adverse events, predominantly gastrointestinal.218,219 Specifically, GLP-1RAs have been strongly linked to gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, with incidence rates influenced by dosage and concomitant therapies.78 Moreover, the use of GLP-1RAs may be associated with an elevated risk of pancreatitis and thyroid-related disorders, although these associations have not been definitively established.220 Analysis of data from the US Food and Drug Administration Adverse Event Reporting System revealed that GLP-1RAs, particularly semaglutide and exenatide, are significantly correlated with gastrointestinal adverse events, including nausea, vomiting, delayed gastric emptying, and pancreatitis.221 Dual receptor agonists targeting GLP-1 and GIP, such as tirzepatide, have also exhibited promising efficacy in diabetes management, notably in terms of weight reduction and glycemic control
Starting doses of basal insulin (NPH or analogue) are estimated based on body weight (0.10.2 U/kg per day) and the degree of hyperglycaemia, with individualised titration as needed
& Iiri, T
In midlife, it is important to get clear on the goals of nutrition and lifestyle interventions
.webp)
